Clinical Research Center & Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China.
Psychopharmacology (Berl). 2020 May;237(5):1421-1433. doi: 10.1007/s00213-020-05469-0. Epub 2020 Mar 4.
RATIONALE: The rapid-onset and long-lasting antidepressant properties of ketamine have prompted investigations into a variety of agents that target N-methyl-D-aspartate receptors (NMDARs) for the treatment of major depressive disorder (MDD). According to the literature, ifenprodil (a GluN2B-containing NMDAR antagonist) can potentiate the antidepressant-like effects of certain antidepressant drugs in mice. Here, we report that a single injection of ifenprodil (3 mg/kg, intraperitoneally (i.p.)) was sufficient to provoke rapid antidepressant-like effects in chronic unpredictable mild stress (CUMS) rats. Moreover, ifenprodil activated mTOR signaling and reversed the CUMS-induced elevation of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in the hippocampus after acute administration. Unfortunately, in our study, ifenprodil had no influence on corticosterone levels in the plasma. Our data indicate that ifenprodil per se might exert antidepressant-like effects by modulating neuroplasticity and inflammatory processes rather than the typical hormonal factors affected by stressors. OBJECTIVES: To explore the potential rapid antidepressant-like effects and mechanisms of ifenprodil, a GluN2B subunit-selective NMDAR antagonist. METHODS: Male Sprague-Dawley rats were used in 3 separate experiments. In experiment 1, we used the forced swim test (FST) and sucrose preference test (SPT) to identify the rapid antidepressant-like effects of ifenprodil in chronic unpredictable mild stress (CUMS) rats after acute administration. In experiment 2, we assessed neurochemical changes involved in synaptic plasticity within the hippocampus of CUMS rats. In experiment 3, we assessed the levels of corticosterone in the plasma and proinflammatory cytokines in the hippocampus in CUMS rats after ifenprodil treatment. RESULTS: Ifenprodil rapidly ameliorated depressive-like behaviors in the FST and SPT, activated mTOR signaling, dephosphorylated eukaryotic elongation factor 2, enhanced BDNF expression, and promoted the synthesis of the synaptic protein GluA1 synthesis after acute administration. Moreover, ifenprodil reversed the CUMS-induced elevation of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in the hippocampus after acute administration. Unfortunately, ifenprodil had no influence on corticosterone levels in the plasma in our study. CONCLUSIONS: Our data indicate that ifenprodil per se might exert antidepressant-like effects through its effects on neuroplasticity and inflammatory processes rather than the typical hormonal factors affected by stressors.
背景:氯胺酮具有快速起效和持久的抗抑郁作用,这促使人们研究各种靶向 N-甲基-D-天冬氨酸受体(NMDAR)的药物,以治疗重度抑郁症(MDD)。根据文献报道,ifenprodil(一种含有 GluN2B 的 NMDAR 拮抗剂)可增强某些抗抑郁药在小鼠中的抗抑郁样作用。在这里,我们报告单次注射 ifenprodil(3mg/kg,腹腔内(i.p.))足以在慢性不可预测的轻度应激(CUMS)大鼠中引发快速的抗抑郁样作用。此外,ifenprodil 在急性给药后激活了 mTOR 信号通路,并逆转了 CUMS 引起的海马体中白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的升高。不幸的是,在我们的研究中,ifenprodil 对血浆中的皮质酮水平没有影响。我们的数据表明,ifenprodil 本身可能通过调节神经可塑性和炎症过程而不是应激源影响的典型激素因素发挥抗抑郁样作用。
目的:探讨 GluN2B 亚单位选择性 NMDAR 拮抗剂 ifenprodil 的潜在快速抗抑郁样作用及其机制。
方法:雄性 Sprague-Dawley 大鼠用于 3 项单独的实验。在实验 1 中,我们使用强迫游泳试验(FST)和蔗糖偏好试验(SPT)来确定 ifenprodil 在慢性不可预测轻度应激(CUMS)大鼠急性给药后的快速抗抑郁样作用。在实验 2 中,我们评估了 CUMS 大鼠海马体内参与突触可塑性的神经化学变化。在实验 3 中,我们评估了 ifenprodil 治疗后 CUMS 大鼠血浆中的皮质酮水平和海马体中的促炎细胞因子水平。
结果:ifenprodil 可快速改善 FST 和 SPT 中的抑郁样行为,激活 mTOR 信号通路,使真核延伸因子 2 去磷酸化,增强脑源性神经营养因子的表达,并促进突触蛋白 GluA1 的合成。此外,ifenprodil 还逆转了急性给药后 CUMS 引起的海马体中白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的升高。不幸的是,在我们的研究中,ifenprodil 对血浆中的皮质酮水平没有影响。
结论:我们的数据表明,ifenprodil 本身可能通过其对神经可塑性和炎症过程的影响而不是应激源影响的典型激素因素发挥抗抑郁样作用。
Int J Neuropsychopharmacol. 2014-12-25
Mol Cell Neurosci. 2023-3
Behav Brain Res. 2021-2-5
Korean J Physiol Pharmacol. 2023-9-1
IBRO Neurosci Rep. 2022-9-5
Biomedicines. 2023-4-23
Life (Basel). 2022-1-28